Gismo Therapeutics was founded on breakthrough science in the field of Glycosaminoglycan (GAG)-Interacting Small Molecules (GISMO), invented by its founder Dr. Paul Gregor. The program provides a new hypothesis for the cause of Alzheimer’s and Parkinson’s Disease, and is aimed to develop innovative oral therapeutics with a novel mechanism of action and a hitherto unexplored therapeutic principle.


The mechanism of action of GISMO compounds is new and proprietary. Patents to cover GISMO technology are pending. The attached video is for illustration purposes only. All rights are reserved.


GTC-3000 – Alzheimer’s Disease: This project aims to develop a novel disease modifying therapeutic, a GISMO compound targeting pathological consequences of glycosaminoglycan, beta-amyloid and Tau biology and their association. This project has been awarded a SBIR grant from NIA/NIH. Lead compounds have been identified and patent applications are being filed.

GTC-5000 – Parkinson’s Disease: This project, based on advances in alpha-synuclein and GAG biology, aims to develop a novel disease-modifying drug for Parkinson’s Disease and other synucleinopathies. This project has been awarded a Michael J. Fox Foundation for Parkinson’s Disease grant.

GTC-6000 – Alzheimer’s Disease: This project is based on advances in Tau and GAG biology, and aims to provide a new medicine for Alzheimer’s Disease, Frontotemporal Dementia and other tauopathies.

more about Alzheimer’s Disease
more about Parkinson’s Disease